|
|
|
| home > ebr > Autumn 2004 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR. |
 |
| |
|
|
| In her Editor's Letter, Dr Helen Tayton-Martin takes a look at the topics in this issue |
|
|
|
|
| Dr Majid Mehtali, Vice President of Research & Development at Vivalis SA, underlines the potential of Embryonic Stem Cells: Current and Future Industrial Applications |
|
|
| Unravelling the Mysteries of Alzheimer's - the search for a cure continues, by G Steven Burrill, CEO of Burrill & Company |
|
|
| Sunil Saini, Director of Biomaterials at Therics, maps the development of a new domain in A Perspective in Orthopaedic Tissue Engineering |
|
|
| Hans Herklots, Media and Investor Relations Director at IsoTis OrthoBiologics, looks at the potential transformation of orthopaedics, in Biologics are Entering the Orthopaedic Arena |
|
|
|
| How are ideas transformed into a thriving business? Nigel Wild, Managing Director of Oxfordshire BioTechNet Ltd, discusses the options in Funding and Mentoring - The Keys to the Biotech Kingdom |
|
|
| In Technology Transfer from Universities, Tom Hockaday, Executive Director of Isis Innovations Ltd, welcomes the continuing interest in collaboration between academia and the business community |
|
|
| Incubators must form an integral part of our infrastructure for supporting young companies, asserts Toni Wanklin, Development Manager at UK Business Incubation, in Breaking Through The Barrier: How Bio-Incubators Support Tomorrow's World-Class Entrepreneurs |
|
|
| Fiona Brown, Public Relations Consultant, considers today's funding environment and the particular hurdles inherent in biotechnology in Uniting Science and Business: The Challenges for Biotech Start-ups |
|
|
| Science, finance and IPR: conditions for Finnish entrepreneurs uncovered in Challenges for Biotech Start-Ups: A Nordic Perspective, by Professor Kalevi Kairemo, Medical Director and Dr Oula Pe-ate Medina, CEO of CTT Cancer Targeting Technologies |
|
|
| Continuing from Part 1 in our summer issue, Beyond Financial Analysis - Scientific Due Diligence in Pharma and Biotech: Part 2 focuseson clinical trials. By Dr Konrad Burk, Founder of ClinDescience GmbH, William McCulloch, CMO of Gloucester Pharmaceuticals, Dr Alexander von Nieciecki, CEO of BioProof, and Dr Wolfgang Meyer, Senior Director of European Drug Regulatory Affairs and Dr Benno Rattel, Senior Director of Drug Development at GPC Biotech AG |
|
|
|
| Valuing Innovation: Patient Access to Novel Therapies, by Alastair Kent, Director of the Genetic Interest Group, explores the disjunction between scientific advances and practical resources |
|
|
| Dr Sarah Rawlings, Policy and Information Officer at Breakthrough Breast Cancer, examines the 'postcode lottery' of UK health care in NICE Implementation - The Patient Perspective |
|
|
|
| Dr Stephen Hammond, CEO of Scottish Biomedical, investigates the factors to be weighed in the Successful Outsourcing of Preclinical Drug Discovery |
|
|
| In Electronic Diary Solutions: Enhanced Collection of Patient Reported Outcomes Data, Dr Bill Byrom, Product Development Director at ClinPhone Group Ltd, details alternatives to the traditional paper-based diary that can reduce the likelihood of distorted results |
|
|
| Ivan N Rich, Founder, Chairman and CEO of HemoGenix, Inc, discusses Stem Cell Haemotoxicity Testing to Predict Toxic Side-Effects and as a Tool for Safety Monitoring during Drug Development |
|
|
| Dr Wendy M Shaw, Associate Director (Europe) of the Late Phase Group at Kendle International Inc, explains the function of post-marketing surveillance in recording and studying new adverse drug reactions in Opportunities and Challenges of Pan European Post-Marketing Surveillance Programmes |
|
|
|
| Identifying Appropriate RNA Interference Drug Candidates opens the door to a whole new class of treatments - by Dr David A Bumcrot, Director, Preclinical at Alnylam Pharmaceuticals, Inc |
|
|
| Angelika Bonin-Debs, Director of Business Development and Strategic Alliances at Xantos Bioscience, charts the advent of RNAi and its role in Loss-of-Function and Gain-of-Function - Two Complementing Genome-Wide Technologies For Drug Discovery and Target Validation |
|
|
| Automation and Robotics in High Throughput Protein Crystallography explained by Bernhard Rupp, Macromolecular Crystallography and Structural Genomics Group of the Lawrence Livermore National Laboratory, University of California |
|
|
| Methods of column protection are presented in Syringe Filter Efficiency and the Effect of Filtration on HPLC Column Life, by Dr Weibing Ding, Senior Staff Scientist and Larry Scheer, Business Development Manager at Pall Corporation |
|
|
|
| Regu Chandar Gnanapragasam, Assistant Manager of the Industrial & Trade Division of the Penang Development Corporation, Simon Saxby, Chief Executive Officer at Alpha Biologics Sdn Bhd and Dr Malcolm Blackwell, Chief Executive Officer at Progenix Research Sdn Bhd, unveil a new development zone for biotech in Malaysian Biotechnology Initiative for the State of Penang |
|
|
|
| Innovation, investment and government support - Nicola Watkinson, Senior Investment Commissioner, Europe, at Invest Australia, sets the scene in Australian Biotechnology - An Untapped Opportunity |
|
|
|
| CMP Information anticipate this year's BioTech Hot Spot, a unique networking facility at CPhI Worldwide/ICSE |
|
|
| Answering the growing need for partnership opportunities, BIO-Europe 2004: Europe's Largest Partnering Conference, Provides a Platform for Deal-Making and Investors |
|
|
| Tracing global industry trends in Resurgent, Refocused and On the Threshold - Insights from Ernst & Young's 11th Annual Global Biotechnology Report, by EBR Editor Helen Tayton-Martin |
|
|
| Advokat Lars Rambe, Head of Life Science at Adokatfirman Delphi & Co, compares IP systems in the EU and US in Commercialisation of Inventions from Scandinavian Universities - A Challenge and an Opportunity |
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment
3P and Zhittya began their relationship at the beginning of 2019
with 3P being selected as the CDMO to transfer the process for scaling
up and performing cGMP manufacturing for clinical studies. After
successfully achieving transfer of the process, 3P anticipates
manufacturing of the first cGMP batch by the second quarter of 2020.
More info >> |
|
 |
White Papers |
 |
|
ConsulTech GmbH
ConsulTech GmbH
ConsulTech is a consulting company founded in 1992. Since then, we have
been supporting biotech-nology, pharmaceutical and medical technology
companies as well as research institutions with the entire process of
setting-up and executing proposals for R&D projects. In projects
funded by the European Commission, ConsulTech supports the coordinator
by resuming administrative tasks allow-ing coordinators and partners to
fully concentrate on the scientific and technical success of the
pro-ject. We solve financial and administrative issues, organise
meetings, take care of the timely delivery of milestones and reports and
much more.
More info >> |
|
 |
Industry Events |
 |
World Vaccine Congress Europe
18-21 October 2020, Barcelona, Spain
The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >> |
|
|
